234
Participants
Start Date
August 31, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
June 30, 2008
AL-208
1 dose of 300 mg
Placebo
1 dose of placebo
NYU Medical Center, New York
Consultants in Cardiovascular Diseases Inc., Erie
Inova Fairfax Hospital, Falls Church
Cardiac and Thoracic Surgical Associates, Ltd., Mechanicsville
Carolina Cardiovascular Surgical Associates, PA, Raleigh
Duke University Medical Center, Durham
Memory Assessment and Research Services, Wilmington
Piedmont Hospital Research Institute, Atlanta
The Atlanta Heart and Vascular Research Group, Atlanta
Jacksonville Center for Clinical Research, Jacksonville
Miami Research Associates, South Miami
Vanderbilt University, Nashville
Clinical Research Solutions, PC, Knoxville
St. Vincent Mary Medical Center, Toledo
Indiana/Ohio Heart Cardiothoracic and Vascular Surgeons, Fort Wayne
Cardiothoracic Associates, Flint
Chicago Heart Institute and Vein Clinic, Elk Grove Village
Illinois Heart and Vascular Foundation, Hindsdale
Rush University Medical Center, Chicago
Clinical Cardiovascular Research Center, Dallas
St. Luke's Episcopal Hospital, Houston
Physicians Clinical Research Corp., Laguna Hills
Sacramento Heart and Vascular Research Center, Sacramento
Multicare Health Systems, Tacoma
Brigham & Women's Hospital, Boston
Tulsa Clinical Resesarch, LLC, Tulsa
London health Sciences Centre, London
Toronto General Hospital, Toronto
Lead Sponsor
Allon Therapeutics
INDUSTRY